JP6490574B2 - 不溶性フィブリンに対する抗体 - Google Patents

不溶性フィブリンに対する抗体 Download PDF

Info

Publication number
JP6490574B2
JP6490574B2 JP2015503025A JP2015503025A JP6490574B2 JP 6490574 B2 JP6490574 B2 JP 6490574B2 JP 2015503025 A JP2015503025 A JP 2015503025A JP 2015503025 A JP2015503025 A JP 2015503025A JP 6490574 B2 JP6490574 B2 JP 6490574B2
Authority
JP
Japan
Prior art keywords
antibody
fibrinogen
fibrin
amino acid
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015503025A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2014133093A1 (ja
Inventor
保広 松村
保広 松村
正浩 安永
正浩 安永
洋平 久田
洋平 久田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Cancer Center Japan
Original Assignee
National Cancer Center Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Cancer Center Japan filed Critical National Cancer Center Japan
Publication of JPWO2014133093A1 publication Critical patent/JPWO2014133093A1/ja
Application granted granted Critical
Publication of JP6490574B2 publication Critical patent/JP6490574B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745Assays involving non-enzymic blood coagulation factors
    • G01N2333/75Fibrin; Fibrinogen
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/22Haematology
    • G01N2800/226Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2015503025A 2013-02-28 2014-02-27 不溶性フィブリンに対する抗体 Active JP6490574B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013039625 2013-02-28
JP2013039625 2013-02-28
PCT/JP2014/054925 WO2014133093A1 (ja) 2013-02-28 2014-02-27 不溶性フィブリンに対する抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018137861A Division JP7012360B2 (ja) 2013-02-28 2018-07-23 不溶性フィブリンに対する抗体

Publications (2)

Publication Number Publication Date
JPWO2014133093A1 JPWO2014133093A1 (ja) 2017-02-02
JP6490574B2 true JP6490574B2 (ja) 2019-03-27

Family

ID=51428352

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015503025A Active JP6490574B2 (ja) 2013-02-28 2014-02-27 不溶性フィブリンに対する抗体
JP2018137861A Active JP7012360B2 (ja) 2013-02-28 2018-07-23 不溶性フィブリンに対する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018137861A Active JP7012360B2 (ja) 2013-02-28 2018-07-23 不溶性フィブリンに対する抗体

Country Status (5)

Country Link
US (1) US9429584B2 (enExample)
EP (2) EP2963059B1 (enExample)
JP (2) JP6490574B2 (enExample)
ES (1) ES2673583T3 (enExample)
WO (1) WO2014133093A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016167227A1 (ja) * 2015-04-13 2016-10-20 国立研究開発法人国立がん研究センター 不溶性フィブリンに対する抗体
TWI617319B (zh) 2015-09-01 2018-03-11 免疫功坊股份有限公司 用以治療病理性血栓的融合蛋白
BR112019010064A2 (pt) 2016-11-18 2019-10-01 Astellas Pharma Inc novo fragmento fab do anticorpo muc1 anti-humano
EP3548515A1 (en) * 2016-12-01 2019-10-09 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
BR112019016336A2 (pt) 2017-02-10 2020-03-31 Regeneron Pharmaceuticals, Inc. Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
EP3620471A4 (en) 2017-05-02 2021-01-06 National Cancer Center Japan ANTIBODY-ANTI-FIBRIN DRUG CONJUGATE INSOLUBLE, POSSIBLE TO BE CLIVID BY PLASMINE
TWI795415B (zh) * 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類CEACAM5抗體Fab片段
KR102880156B1 (ko) 2017-07-24 2025-11-05 리제너론 파마슈티칼스 인코포레이티드 항cd8 항체 및 이의 용도
BR112020023420A8 (pt) 2018-05-17 2022-07-05 Astellas Pharma Inc Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante
AU2019343131A1 (en) * 2018-09-17 2021-04-29 Icahn School Of Medicine At Mount Sinai Anti-LILRB2 antibodies and methods of use thereof
EP3865154A4 (en) 2018-10-10 2022-11-09 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY FAB FRAGMENT COMPLEX AT LABELED ANTI-HUMAN SITE
WO2021163989A1 (en) * 2020-02-21 2021-08-26 Yinnuolai Biotech Ltd. Anti-baff receptor antibodies and uses thereof
US20230132177A1 (en) * 2020-03-31 2023-04-27 National Cancer Center Fibrin-binding antibody and pharmaceutical composition containing antibody
JP7704339B2 (ja) * 2020-03-31 2025-07-08 国立研究開発法人国立がん研究センター フィブリンクロットを溶解させることに適した融合タンパク質および当該融合タンパク質を含む医薬組成物
EP3916009B1 (en) * 2020-05-26 2023-06-28 Sartorius Lab Instruments GmbH & Co. KG Recombinant proteins based on fibrinogen
EP4506458A1 (en) 2022-04-08 2025-02-12 RIN Institute Inc. Antibody binding to fibrin, fibrinolytic protein containing antibody, and pharmaceutical formulation containing protein
CN118240085B (zh) * 2022-10-08 2025-05-09 东莞市朋志生物科技有限公司 抗纤维蛋白降解产物抗体、检测纤维蛋白降解产物的试剂和试剂盒

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4916070A (en) 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
US5120834A (en) * 1988-06-13 1992-06-09 American Biogenetic Sciences, Inc. Fibrin-specific monoclonal antibody
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
JPH11206387A (ja) 1991-08-28 1999-08-03 Genpharm Internatl Inc 異種免疫グロブリンを作る方法及びそのためのトランスジェニックマウス
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
EP0770628B9 (en) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
KR19990008197A (ko) 1995-04-28 1999-01-25 레이몬드 엠. 위티 면역화된 제노마우스 유래의 인체 항체
JPH08301900A (ja) 1995-04-28 1996-11-19 Shima Kenkyusho:Kk 可溶性フィブリン複合体に対するモノクローナル抗体
JPH09104700A (ja) 1995-10-09 1997-04-22 Bio Rinkusu Kk 抗ヒト可溶性フィブリン抗体及びそれを用いた免疫学的測定法
JP2001354700A (ja) 2000-06-12 2001-12-25 Bio Links Kk モノクロ−ナル抗体及びヒトフィブリン分解産物の測定方法
US8372954B2 (en) 2000-12-22 2013-02-12 National Research Council Of Canada Phage display libraries of human VH fragments
MXPA03012030A (es) 2001-06-26 2005-07-01 Agen Biomedical Ltd Anticuerpos humanizados derivados de dd-3b6/22, especificos para el fragmento de dimero d de fibrina.
JP5222521B2 (ja) 2004-12-28 2013-06-26 積水メディカル株式会社 抗ヒト可溶性フィブリンモノクローナル抗体の製造方法
CN101087877B (zh) 2004-12-28 2012-08-08 第一化学药品株式会社 抗人可溶性血纤蛋白单克隆抗体及使用该抗体的免疫学测定方法
JP5419131B2 (ja) * 2005-12-12 2014-02-19 エーシー イミューン ソシエテ アノニム 治療的特性を有するβ1〜42特異的モノクローナル抗体
AU2007219615B2 (en) * 2006-03-03 2013-11-28 Promis Neurosciences Inc. Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
WO2008096760A1 (ja) 2007-02-05 2008-08-14 Osaka University 新規ヘキサトリエン-β-カルボニル化合物
WO2010055950A1 (ja) 2008-11-17 2010-05-20 財団法人ヒューマンサイエンス振興財団 癌間質の構成因子に対して特異的結合能を有する物質と抗腫瘍性化合物との複合体による新規の癌ターゲティング治療
JP5805363B2 (ja) * 2009-06-26 2015-11-04 和興フィルタテクノロジー株式会社 可溶性凝集体、免疫寛容誘導剤及びその製造方法
JP2012000072A (ja) * 2010-06-18 2012-01-05 Japan Health Science Foundation 新規な抗フィブリン抗体
AR086250A1 (es) * 2011-05-05 2013-11-27 Hoffmann La Roche Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo

Also Published As

Publication number Publication date
US20160011217A1 (en) 2016-01-14
EP3339327A3 (en) 2018-09-19
US9429584B2 (en) 2016-08-30
JP2018193386A (ja) 2018-12-06
WO2014133093A1 (ja) 2014-09-04
JP7012360B2 (ja) 2022-02-14
EP2963059A4 (en) 2017-03-22
ES2673583T3 (es) 2018-06-22
JPWO2014133093A1 (ja) 2017-02-02
EP2963059B1 (en) 2018-04-04
EP2963059A1 (en) 2016-01-06
EP3339327A2 (en) 2018-06-27

Similar Documents

Publication Publication Date Title
JP6490574B2 (ja) 不溶性フィブリンに対する抗体
CA2646329C (en) Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
US8101713B2 (en) Prostate cancer diagnosis and treatment
BR112012029281B1 (pt) anticorpo contra trop-2 humano, anticorpo monoclonal contra trop-2 humano, fragmento de anticorpo derivado de anticorpo, hibridoma, conjugado, composição farmacêutica, uso de composição farmacêutica, método para detectar um tumor e kit para tratar, diagnosticar ou detectar um tumor
ES2615387T3 (es) Anticuerpos contra el antígeno 1 asociado al riñón y fragmentos de unión al antígeno de estos
JP2013522167A (ja) uPAR結合剤及びその使用方法
US6835549B2 (en) Immunoassay method for the diagnosis of gastric intestinal metaplasia associated with gastric carcinoma
WO2017097990A1 (en) Antibodies for treatment and diagnosis of inflammatory bowel disease
WO2011158973A1 (ja) 新規な抗フィブリン抗体
TW201842938A (zh) 可藉由胞漿素切斷之抗不溶性纖維蛋白抗體與藥物之複合體
WO2011090166A1 (ja) 食道癌マーカー
KR20140067047A (ko) 대장암 또는 식도암의 검출용 마커 및 검사 방법
WO2016167227A1 (ja) 不溶性フィブリンに対する抗体
WO2025040093A1 (zh) 靶向gpc3的分子探针以及用途
KR20130135869A (ko) 항 단쇄 제4형 콜라겐 폴리펩타이드 항체 및 이를 포함하는 종양의 진단, 예방 또는 치료용 약제
KR101380057B1 (ko) 췌장암의 진단제 및 치료제
US20140178906A1 (en) Monoclonal antibodies against pcbp-1 antigens, and uses therefor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190227

R150 Certificate of patent or registration of utility model

Ref document number: 6490574

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250